chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph node above left collarbone; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Apr2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 27Apr2021, the patient experienced swollen lymph node above left collarbone. The event swollen lymph node above left collarbone did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph node above left collarbone was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Menstruation delayed
Clinical narrative: Period was 3 days late; Causing cramps both front and lower back for at least 7 days / Period finally started and still cramping; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Apr2021 at 12:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included high BP (blood pressure) and allergy to sulfa drugs. Concomitant medications included labetalol (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Apr2021 at 13:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. On 30Apr2021 at 16:30, the patient's period was 3 days late which was causing cramps, both front and lower back for at least seven days. Then the period finally started and was still cramping. The patient reported that none of which was normal for her. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events period was 3 days late which was causing cramps both front and lower back/ period finally started and still cramping was not resolved at the time of the report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in my left ear; This is a spontaneous report from a contactable healthcare professional, the patient. A 51-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03May2021 at 14:30(at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not did not receive any medications within two weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Apr2021 at 14:30(at the age of 51-years-old) as a single dose for COVID-19 immunisation. On 06May2021 at 12:00 the patient experienced ringing in her left ear. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event ringing in her left ear was not resolved at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Cough
Clinical narrative: Cough since receiving second dose of Pfizer Vaccine. Not constant, but about 5 times daily. It is a deep and dry cough, also unusual for patient.; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EF8731) via an unspecified route of administration in the left arm on 26Apr2021 at 09:45 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 27Apr2021, since receiving the second dose of Pfizer vaccine, the patient experienced cough. Not constant, but about 5 times daily. It was a deep and dry cough, also unusual for the patient. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event cough not constant, but about 5 times daily, deep and dry cough unusual for the patient was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle atrophy, Myalgia
Clinical narrative: Muscle atrophy; Muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left deltoid on 14Apr2021 at 12:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included clonazepam (MANUFACTURER UNKNOWN) from an unknown date for unspecified indication and unknown if ongoing. On 17Apr2021, the patient had muscle atrophy and muscle pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle atrophy and muscle pain was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia, Pain, Pain in extremity
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 04May2021 at 15:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history included type one diabetes - diagnosed at the age of 22 months. The patient was allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included insulin (MANUFACTURER UNKNOWN), taken for type one diabetes from on an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Apr2021 at 15:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 01:00, the patient experienced fever, chills, body aches, headache, muscle aches and arm soreness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, body aches, headache, muscle aches and arm soreness was not resolved at the time of this report. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 04May2021 at 15:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history included type one diabetes - diagnosed at the age of 22 months. The patient was allergic to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included insulin (MANUFACTURER UNKNOWN), taken for type one diabetes from on an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Apr2021 at 15:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 01:00, the patient experienced fever, chills, body aches, headache, muscle aches and arm soreness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, body aches, headache, muscle aches and arm soreness was not resolved at the time of this report. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 26Apr2021 at 18:30 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04May2021 at 11:00, the patient experienced headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headache was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenitis, Menstruation irregular, Pain, Pyrexia
Clinical narrative: "I" had very bad fever; "I" had very bad fever and body aches the next two days.; few weeks later "my" period came a week early; "I" had inflammation in lymph nodes on opposite side of shot.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Feb2021 at 15:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 10Feb2021, the patient had very bad fever and body aches the next two days. On an unknown date in 2021, a few weeks later the patient's period came a week early and had inflammation in lymph nodes on opposite side of shot. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very bad fever and body aches was resolved on an unknown date in Apr2021, while the clinical outcome of the events period came a week early and inflammation in lymph nodes on opposite side of shot was unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Chest pain, Condition aggravated, Fatigue
Clinical narrative: Burning sensation on my esophagus and lungs; swelling of left ankle; I developed a lot of joint pain; Almost like a chest pain; Muscle pain; Right lymph node by neck got very swollen; Allergic reaction to fluoroquinolones (Cipro/Levaquin ) that causes continued pain in joints and muscle weakness. Vaccine exacerbated the symptoms to the point I was laying down for at least 4 of those days.; Vaccine exacerbated the symptoms to the point I was laying down for at least 4 of those days.; Vaccine exacerbated the symptoms to the point I was laying down for at least 4 of those days; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 12Apr2021 at 12:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history included pain in joints and muscle weakness. The patient previously received fluoroquinolones which are (ciprofloxacin) (cipro) (MANUFACTURER UNKNOWN) and levaquin (MANUFACTURER UNKNOWN) and experienced drug allergy. Concomitant medications included escitalopram oxalate (LEXAPRO), clonazepam (MANUFACTURER UNKNOWN) and multivitamins (MANUFACTURER UNKNOWN) started at unknown date for unknown indication. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 12Apr2021 at 16:00, the patient experienced right lymph node by neck got very swollen and swelling of left ankle. The patient developed a lot of joint pain and muscle pain and also felt a burning sensation on esophagus and lungs. Almost like a chest pain. This that took over seven days for all symptoms to go away. Therapeutic measures were not taken as a result of the events. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent SARS-CoV-2 test and was found to be negative. The clinical outcome of the events right lymph node by neck got very swollen, swelling of left ankle, lot of joint pain, muscle pan, burning sensation on esophagus and lungs, almost like a chest pain, muscle weakness and was laying down for at least four of those days was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Joint swelling, Lymphadenopathy, Muscular weakness, Myalgia, SARS-CoV-2 test
Clinical narrative: Burning sensation on my esophagus and lungs; swelling of left ankle; I developed a lot of joint pain; Almost like a chest pain; Muscle pain; Right lymph node by neck got very swollen; Allergic reaction to fluoroquinolones (Cipro/Levaquin ) that causes continued pain in joints and muscle weakness. Vaccine exacerbated the symptoms to the point I was laying down for at least 4 of those days.; Vaccine exacerbated the symptoms to the point I was laying down for at least 4 of those days.; Vaccine exacerbated the symptoms to the point I was laying down for at least 4 of those days; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 12Apr2021 at 12:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history included pain in joints and muscle weakness. The patient previously received fluoroquinolones which are (ciprofloxacin) (cipro) (MANUFACTURER UNKNOWN) and levaquin (MANUFACTURER UNKNOWN) and experienced drug allergy. Concomitant medications included escitalopram oxalate (LEXAPRO), clonazepam (MANUFACTURER UNKNOWN) and multivitamins (MANUFACTURER UNKNOWN) started at unknown date for unknown indication. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 12Apr2021 at 16:00, the patient experienced right lymph node by neck got very swollen and swelling of left ankle. The patient developed a lot of joint pain and muscle pain and also felt a burning sensation on esophagus and lungs. Almost like a chest pain. This that took over seven days for all symptoms to go away. Therapeutic measures were not taken as a result of the events. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent SARS-CoV-2 test and was found to be negative. The clinical outcome of the events right lymph node by neck got very swollen, swelling of left ankle, lot of joint pain, muscle pan, burning sensation on esophagus and lungs, almost like a chest pain, muscle weakness and was laying down for at least four of those days was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Vaccination site bruising, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; This is a spontaneous report from a contactable pharmacist. A 45-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an intramuscular route of administration in the left arm on 03May2021 at 10:15 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an intramuscular route of administration in the left arm on 05Apr2021 at 10:15 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. On 04May2021 at 16:30, the patient experienced redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site. The event resulted in emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On an unknown date, the patient underwent COVID-19 virus test via nasal swab and the result was negative. The clinical outcome of the event redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site vesicles
Clinical narrative: Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; Redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site; This is a spontaneous report from a contactable pharmacist. A 45-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an intramuscular route of administration in the left arm on 03May2021 at 10:15 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an intramuscular route of administration in the left arm on 05Apr2021 at 10:15 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. On 04May2021 at 16:30, the patient experienced redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site. The event resulted in emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On an unknown date, the patient underwent COVID-19 virus test via nasal swab and the result was negative. The clinical outcome of the event redness, swollen, bruising, pain and a blister on the left arm about 6 inches lower than injection site was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Myalgia
Clinical narrative: Swollen lymph node in left armpit area; Muscle pain on opposite side of arm where injection site was; This is a spontaneous report from a non-contactable consumer, the patient. A 17-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the left arm on 29Apr2021 at 14:45 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. The patient did not take any concomitant medications. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021, the patient experienced swollen lymph node in left armpit area, muscle pain on opposite side of arm where the injection site was. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen lymph node in left armpit area and muscle pain on opposite side of arm where the injection site was resolving at the time of the report.  No follow-up attempts are possible. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Nausea, Pyrexia, Sensitive skin
Clinical narrative: Fever; Chills; Nausea; Joint pain; Skin sensitivity; This is a spontaneous report from a non-contactable consumer, the patient. A 19-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration on an unknown date (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On an unknown date, the patient experienced fever, chills, nausea, joint pain, skin sensitivity. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, nausea, joint pain, skin sensitivity were resolved on an unknown date.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Bone pain, Fatigue, Headache, Musculoskeletal stiffness
Clinical narrative: Muscle pain; Joint pain; Bone pain; Muscle stiffness; Headache; Fatigue; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04May2021 at 11:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history and had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included bupropion (MANUFACTURER UNKNOWN) XL for unknown indication from unknown date and unknown if ongoing. On 04May2021, the patient experienced muscle, joint, bone pain, muscle stiffness, headache, fatigue and fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle, joint, bone pain, muscle stiffness, headache, fatigue and fever were recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Muscle pain; Joint pain; Bone pain; Muscle stiffness; Headache; Fatigue; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04May2021 at 11:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history and had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included bupropion (MANUFACTURER UNKNOWN) XL for unknown indication from unknown date and unknown if ongoing. On 04May2021, the patient experienced muscle, joint, bone pain, muscle stiffness, headache, fatigue and fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle, joint, bone pain, muscle stiffness, headache, fatigue and fever were recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Allodynia, Fatigue, Migraine, Pyrexia, Rash
Clinical narrative: Rash; Migraine; Fever; Fatigue; Extreme pain when touching anything like wearing clothes; Skin felt extremely raw; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the left arm on 04May2021 at 12:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included severe multiple allergies, possible autoimmune illness which was undiscovered and seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included lamotrigine (MANUFACTURER UNKNOWN), norethisterone acetate, ethinylestradiol, ferrous fumarate (BLISOVI), propranolol (MANUFACTURER UNKNOWN) and fexofenadine hydrochloride (ALLEGRA); all for unknown indication from unknown date and unknown if ongoing. The patient previously took codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 13Apr2021 at 12:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 15:30, the patient experienced rash, migraine, fever, fatigue, extreme pain when touching anything like wearing clothes, and her skin felt extremely raw. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events rash, migraine, fever, fatigue, extreme pain when touching anything like wearing clothes, and her skin felt extremely raw was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Skin erosion
Clinical narrative: Rash; Migraine; Fever; Fatigue; Extreme pain when touching anything like wearing clothes; Skin felt extremely raw; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the left arm on 04May2021 at 12:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included severe multiple allergies, possible autoimmune illness which was undiscovered and seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included lamotrigine (MANUFACTURER UNKNOWN), norethisterone acetate, ethinylestradiol, ferrous fumarate (BLISOVI), propranolol (MANUFACTURER UNKNOWN) and fexofenadine hydrochloride (ALLEGRA); all for unknown indication from unknown date and unknown if ongoing. The patient previously took codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 13Apr2021 at 12:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 15:30, the patient experienced rash, migraine, fever, fatigue, extreme pain when touching anything like wearing clothes, and her skin felt extremely raw. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events rash, migraine, fever, fatigue, extreme pain when touching anything like wearing clothes, and her skin felt extremely raw was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Discomfort, Dysphagia, Dyspnoea, Fatigue, Lymph node pain
Clinical narrative: About a day or two after receiving my vaccine, I experienced all the normal side effects (fatigue, soreness, etc); About a day or two after receiving my vaccine, I experienced all the normal side effects (fatigue, soreness, etc); The side effect that cause concern for me was the swelling of my lymph nodes under my jawline.; They didnt hurt, but they were tender; Made my throat feel enflamed.; More discomfort than pain; It did affect my breathing; It did affect my breathing and ingestion of food to a degree.; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, about a day or two after receiving his vaccine, the patient experienced all the normal side effects like fatigue, soreness, etc. The side effect that caused concern for the patient was the swelling of his lymph nodes under his jawline. They didn't hurt, but they were tender and made his throat feel enflamed. There was more discomfort than pain. The patient couldn't say any other symptoms arose, but it did affect his breathing and ingestion of food to a degree. It was two weeks post-first dose and the swelling was down a bit, but the lymph nodes still felt tender. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event swelling of lymph nodes under jawline was resolving, while that of they didn't hurt, but they were tender was not resolved. The clinical outcome of the events about a day or two after receiving vaccine, experienced all the normal side effects like fatigue, soreness, etc; throat felt enflamed; there was more discomfort than pain; it did affect breathing and ingestion of food to a degree was unknown at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pain, Pharyngeal inflammation
Clinical narrative: About a day or two after receiving my vaccine, I experienced all the normal side effects (fatigue, soreness, etc); About a day or two after receiving my vaccine, I experienced all the normal side effects (fatigue, soreness, etc); The side effect that cause concern for me was the swelling of my lymph nodes under my jawline.; They didnt hurt, but they were tender; Made my throat feel enflamed.; More discomfort than pain; It did affect my breathing; It did affect my breathing and ingestion of food to a degree.; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, about a day or two after receiving his vaccine, the patient experienced all the normal side effects like fatigue, soreness, etc. The side effect that caused concern for the patient was the swelling of his lymph nodes under his jawline. They didn't hurt, but they were tender and made his throat feel enflamed. There was more discomfort than pain. The patient couldn't say any other symptoms arose, but it did affect his breathing and ingestion of food to a degree. It was two weeks post-first dose and the swelling was down a bit, but the lymph nodes still felt tender. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event swelling of lymph nodes under jawline was resolving, while that of they didn't hurt, but they were tender was not resolved. The clinical outcome of the events about a day or two after receiving vaccine, experienced all the normal side effects like fatigue, soreness, etc; throat felt enflamed; there was more discomfort than pain; it did affect breathing and ingestion of food to a degree was unknown at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Swelling face
Clinical narrative: Face swelling; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04May2021, at 09:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies to latex, amalgam, shellfish and wool. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. On 04May2021 at 09:00, the patient experienced face swelling and nausea. It was unknown whether the patient received any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events face swelling and nausea was unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0172) via an unspecified route of administration in the left arm on 05May2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included montelukast sodium (MANUFACTURER UNKNOWN) and CVS multivitamins (MANUFACTURER UNKNOWN) all from unknown date for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8729) via an unspecified route of administration in the left arm on 13Apr2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 06May2021 at 00:00, within 12 hours of second dose the patient experienced chills, severe headache, fever of 101 and fatigue. On 06May2021 at 00:00, the patient underwent body temperature and the result was 101 (unspecified units). The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, severe headache, fever of 101 and fatigue were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Feeling itchy on stomach and back; Rash all over chest, neck, stomach and back; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration on the left arm on 30Apr2021 at 11:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within 4 weeks prior to the vaccination. The patient did not receive any medication within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EW0167) via an unspecified route of administration in the left arm on 09Apr2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 01May2021, within 24 hours of the vaccine, the patient began to feel itchy on her stomach and back. The itchiness proceeded to get worse and she noticed that she had a rash all over her chest, neck, stomach and back. On 04May2021, it was day 4 of the rash and continued itchiness. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. It was unknown if any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events felt itchy on stomach and back and rash all over chest, neck, stomach and back was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Headache, SARS-CoV-2 test
Clinical narrative: Two days after receiving vaccine (5/1) I suddenly lost the ability to taste; Two days after receiving vaccine (5/1) I suddenly lost the ability to smell; The day after receiving vaccine (4/30) I had a severe and debilitating headache; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 29Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to mollusks. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included bupropion (MANUFACTURER UNKNOWN), spironolactone (MANUFACTURER UNKNOWN), terbinafine (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN); all for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 07Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. On 30Apr2021, the day after receiving vaccine, the patient had a severe and debilitating headache. On 01May2021, two days after receiving vaccine she suddenly lost the ability to taste and smell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. The patient was alarmed because the events appeared to not be a known side effect of the vaccine, so the following day, on 02May2021, she got a Polymerase Chain Reaction (PCR) test done for COVID-19, to see if she had somehow contracted COVID and the result was negative; so, she was sure that the temporary loss of taste and smell was due to the vaccine. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events suddenly lost the ability to taste and smell was resolved on 02May2021, while that of had a severe and debilitating headache was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.